CWHM-12
Cat. No.：YN300049
CAS No. ：1564286-55-0
| 产品名称: | CWHM-12 |
| CAS No.: | 1564286-55-0 |
| Chemical Name: | (3S)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-[3-bromo-5-(1,1-dimethylethyl)phenyl]-β-alanine |
| Synonyms: | CWHM12;CWHM-12;(3S)-3-(3-bromo-5-(tert-butyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid;CWHM 12;GTPL10495;AOB2397;(3S)-3-(3-bromo-5-tert-butylphenyl)-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4, |
| 分子量: | 590.47 |
| 分子式: | C₂₆H₃₂BrN₅O₆ |
| SMILES: | O=C(CNC(C1=CC(NC2=NCC(O)CN2)=CC(O)=C1)=O)N[C@H](C3=CC(C(C)(C)C)=CC(Br)=C3)CC(O)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | CWHM-12是αV整联蛋白的有效抑制剂，抑制αvβ8，αvβ3，αvβ6和αvβ1的IC50值分别为0.2，0.8，1.5，1.8 nM。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Ruoslahti, E., and Öbrink, B.Common principles in cell adhesionExp. Cell Res.227(1),1-11(1996)
Henderson, N.C., Arnold, T.D., Katamura, Y., et al.Selective αv integrin depletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organsNat. Med.19(12),1-12(2013)
Ulmasov, B., Newschwander-Tetri, B.A., Lai, J., et al.Inhibitors of Arg-Gly-Asp-binding integrins reduce development of pancreatic fibrosis in miceCell. Mol. Gastroenterol. Hepatol.2(4),499-518(2016)
